- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
- Interventions
- Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6,452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1405
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 833
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cervical Cancer
- Interventions
- tisotumab vedotin, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 53
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 28 more
- Conditions
- Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer, Cervical Cancer
- Interventions
- Pedometer-based Walking Program
- Behavioral
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Cervical Cancer
- Interventions
- Intervention
- Behavioral
- Lead sponsor
- California State University, Fullerton
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 1,014 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
- Interventions
- ²¹²Pb-DOTAM-GRPR1
- Drug
- Lead sponsor
- Orano Med Theranostics, SAS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more
- Conditions
- Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
- Interventions
- Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review
- Other · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 23
- States / cities
- Dublin, California • Fremont, California • Fresno, California + 19 more
- Conditions
- Gynecologic Cancer, Endometrial Cancer, Cervical Cancer, Quality of Life, Opioid Use
- Interventions
- Headspace Smartphone Application
- Behavioral
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cervical Cancer
- Interventions
- pemetrexed disodium
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • Modesto, California • Hartford, Connecticut + 18 more
- Conditions
- Ovarian Cancer, Endometrial Cancer, Cervical Cancers, Vulvar Cancers, Uterine Cancer, Cervix Cancer, Ovary Cancer
- Interventions
- GYNCOG
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
- Interventions
- Vigil, Atezolizumab
- Biological · Drug
- Lead sponsor
- Gradalis, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more
- Conditions
- Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Advanced Solid Tumor, Advanced Cancer
- Interventions
- PHN-010
- Drug
- Lead sponsor
- Pheon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- Orlando, Florida • Boston, Massachusetts • New York, New York + 5 more
- Conditions
- Advance Care Planning
- Interventions
- video, usual care
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Renal Cell Carcinoma, Lung Carcinoma, Cervical Carcinoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Human Papilloma Virus (HPV), Cervical Cancers
- Interventions
- Self-sampling with urine, Self-sampling with swab, In-clinic Pap/HPV co-testing
- Device
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 30 Years to 65 Years · Female only
- Enrollment
- 735 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
- Interventions
- GTL001+, Aldara
- Drug
- Lead sponsor
- Genticel
- Industry
- Eligibility
- 25 Years to 65 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Louisville, Kentucky • Raleigh, North Carolina • Columbus, Ohio + 1 more
- Conditions
- Cervical Cancer, Human Papillomavirus Infection
- Interventions
- Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation
- Behavioral
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 30 Years to 65 Years · Female only
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer
- Interventions
- OncoPrism™ assay
- Diagnostic Test
- Lead sponsor
- Cofactor Genomics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Atypical Squamous Cell of Undetermined Significance, Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Health Status Unknown, Human Papillomavirus Infection, Low Grade Cervical Squamous Intraepithelial Neoplasia, Stage 0 Cervical Cancer
- Interventions
- Cervical Papanicolaou Test, Cytology Specimen Collection Procedure, Questionnaire Administration, Screening Method
- Other · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 1,335 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Seattle, Washington
- Conditions
- Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Hepatocellular Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma
- Interventions
- LY3435151, Pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
- Interventions
- XmAb20717
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 12 more
- Conditions
- Cervix Neoplasms
- Interventions
- Healing Touch Therapy, Relaxation Therapy, Standard Care
- Behavioral
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity
- Interventions
- triapine, cisplatin, external beam radiation therapy, quality-of-life assessment, questionnaire administration, fludeoxyglucose F 18, positron emission tomography, computed tomography
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
- Interventions
- Reiki therapy
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cervical Cancer, Breast Cancer, Health Behavior
- Interventions
- Educational Intervention
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland